The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.
BACKGROUND
Androgens bind to the androgen receptor (AR) in prostate cells and are essential survival factors for healthy prostate epithelium. Most untreated prostate cancers retain some dependence upon the AR and respond, at least transiently, to androgen ablation therapy. However, the relationship between endogenous androgen levels and cancer etiology is unclear. High levels of androgens have traditionally been viewed as driving abnormal proliferation leading to cancer, but it has also been suggested that low levels of androgen could induce selective pressure for abnormal cells. We formulate a mathematical model of androgen regulated prostate growth to study the effects of abnormal androgen levels on selection for pre-malignant phenotypes in early prostate cancer development.


RESULTS
We find that cell turnover rate increases with decreasing androgen levels, which may increase the rate of mutation and malignant evolution. We model the evolution of a heterogeneous prostate cell population using a continuous state-transition model. Using this model we study selection for AR expression under different androgen levels and find that low androgen environments, caused either by low serum testosterone or by reduced 5alpha-reductase activity, select more strongly for elevated AR expression than do normal environments. High androgen actually slightly reduces selective pressure for AR upregulation. Moreover, our results suggest that an aberrant androgen environment may delay progression to a malignant phenotype, but result in a more dangerous cancer should one arise.


CONCLUSIONS
The model represents a useful initial framework for understanding the role of androgens in prostate cancer etiology, and it suggests that low androgen levels can increase selection for phenotypes resistant to hormonal therapy that may also be more aggressive. Moreover, clinical treatment with 5alpha-reductase inhibitors such as finasteride may increase the incidence of therapy resistant cancers.
Eikenberry
Steffen E
SE
Department of Mathematics and Statistics, Arizona State University, Tempe, AZ 85287, USA.
Nagy
John D
JD
Kuang
Yang
Y
D000728:Androgens / Q000494:pharmacology*; D000818:Animals; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D008962:Models, Theoretical; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D011944:Receptors, Androgen / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism
D000728:Androgens; D011944:Receptors, Androgen; D013739:Testosterone
Mol Endocrinol. 1990 Jan;4(1):22-8
2325667
J Natl Cancer Inst. 1988 Sep 21;80(14):1138-47
3411627
Q Rev Biol. 1991 Mar;66(1):1-22
2052670
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):261-6
17113983
Urology. 1999 Mar;53(3):574-80
10096387
Biochem J. 1976 Oct 15;160(1):11-21
1008839
Lancet. 2000 Apr 29;355(9214):1491-8
10801170
Integr Comp Biol. 2007 Aug;47(2):317-28
21672841
J Urol. 1989 May;141(5):1139-42
2651713
Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E952-64
16757547
J Urol. 1986 Nov;136(5):1038-40
3095566
J Urol. 2005 Jun;173(6):1935-7
15879785
Nat Rev Cancer. 2006 Dec;6(12):924-35
17109012
Mol Cell Proteomics. 2006 Nov;5(11):2031-43
16837577
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12999-3004
9371789
Acta Endocrinol (Copenh). 1981 Dec;98(4):634-40
7304086
Endocr Rev. 2004 Apr;25(2):276-308
15082523
J Clin Endocrinol Metab. 1996 Feb;81(2):814-9
8636309
Nat Rev Cancer. 2004 Nov;4(11):891-9
15516961
Nat Genet. 2006 Apr;38(4):468-73
16565718
Cancer Res. 1981 Feb;41(2):619-23
7448809
J Biol Chem. 1992 Sep 25;267(27):19548-54
1527072
Semin Cancer Biol. 2005 Dec;15(6):474-83
16043360
Artif Life. 2000 Fall;6(4):325-45
11348585
Biol Reprod. 1998 Nov;59(5):1163-70
9780323
Eur Urol. 2005 Mar;47(3):308-12
15716191
J Urol. 2009 Apr;181(4):1642-57
19249063
Cancer Res. 2001 Apr 1;61(7):2892-8
11306464
Nat Rev Cancer. 2007 Mar;7(3):213-21
17301845
Endocr J. 2001 Oct;48(5):573-8
11789562
J Clin Oncol. 2005 Oct 20;23(30):7546-54
16234520
Nature. 1952 Apr 12;169(4302):628-9
14929259
J Clin Invest. 1996 Dec 1;98(11):2558-63
8958218
Mol Nutr Food Res. 2008 Jan;52(1):114-30
18080240
Trends Ecol Evol. 1993 Aug;8(8):275-9
21236168
Am J Pathol. 2007 Oct;171(4):1334-41
17717140
IUBMB Life. 1999 Jul;48(1):41-7
10791914
Radiat Environ Biophys. 1990;29(4):249-62
2281132
Biochim Biophys Acta. 1985 Sep 27;842(1):1-11
2412591
J Theor Biol. 2001 Dec 7;213(3):315-31
11735284
J Natl Cancer Inst. 1997 Jan 1;89(1):40-8
8978405
Cancer. 1998 Sep 15;83(6):1170-3
9740082
Nat Med. 2004 Jan;10(1):33-9
14702632
Scand J Urol Nephrol Suppl. 1994;157:41-7
7939452
Cancer. 1993 Dec 15;72(12 Suppl):3788-92
7504577
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091
18425978
Biol Reprod. 1994 Oct;51(4):675-84
7819449
Trends Biochem Sci. 2001 Oct;26(10):597-604
11590012
J Cell Biol. 2007 Apr 9;177(1):63-72
17420290
Math Biosci Eng. 2005 Apr;2(2):381-418
20369929
Bull Math Biol. 2004 Jul;66(4):663-87
15210312
Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1375-84
15298961
Proc Natl Acad Sci U S A. 1989 Jan;86(1):327-31
2911578
Endocrinology. 2003 Apr;144(4):1257-65
12639908
Nat Rev Cancer. 2003 Mar;3(3):226-31
12612657
Am J Pathol. 1998 Jan;152(1):1-9
9422516
Biol Reprod. 1995 Sep;53(3):609-19
7578685
Urology. 1989 May;33(5 Suppl):53-6
2775378
J Urol. 2003 May;169(5):1670-5
12686805
J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83
17848673
J Steroid Biochem Mol Biol. 1996 Aug;58(5-6):539-49
8918980
Science. 1976 Oct 1;194(4260):23-8
959840
Endocrinology. 2001 Sep;142(9):4066-75
11517186
Adv Exp Med Biol. 2006;588:165-70
17089888
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):86-91
16434592
J Urol. 2006 Oct;176(4 Pt 1):1387-91
16952639
Mol Cell Endocrinol. 1993 Feb;91(1-2):43-9
8472853
Urol Int. 2007;79(1):13-8
17627161
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Am J Pathol. 2003 Dec;163(6):2513-22
14633623
Endocrinology. 1999 Oct;140(10):4509-15
10499505
J Cell Biochem. 2001;81(3):437-44
11255226
J Biol Chem. 1976 Sep 25;251(18):5620-9
184085
N Engl J Med. 2003 Jul 17;349(3):215-24
12824459
Endocrinology. 1995 Feb;136(2):741-8
7835306
Br J Cancer. 2000 Jan;82(1):39-45
10638964
Eur J Cancer. 2007 Dec;43(18):2669-77
17996442
Endocrinology. 2002 Dec;143(12):4897-906
12446617
JAMA. 1991 Feb 6;265(5):618-21
1824790
Am J Pathol. 1996 May;148(5):1567-76
8623925
Prostate. 1988;13(3):249-56
3211806
Eur J Cancer Clin Oncol. 1984 Apr;20(4):477-82
6426967
Prostate. 1986;8(3):293-300
3703748
Int J Cancer. 2004 Jan 20;108(3):418-24
14648709
World J Urol. 1995;13(5):297-305
8581001
Neoplasia. 2004 Nov-Dec;6(6):697-704
15720795
Cancer Res. 1999 Sep 1;59(17):4161-4
10485446
Oncogene. 2004 Dec 2;23(56):9111-9
15489889
Trends Ecol Evol. 2005 Oct;20(10):545-52
16701433
Endocrinology. 2000 Feb;141(2):821-32
10650965
Mol Endocrinol. 1990 Nov;4(11):1636-46
2177837
Cancer Res. 1984 May;44(5):1998-2010
6370422
Prostate. 2001 Apr;47(1):52-8
11304729
Cancer Res. 2003 Jul 15;63(14):3847-54
12873971
J Cell Sci. 2005 Sep 15;118(Pt 18):4187-98
16141232